SERA
Sera Prognostics, Inc.Healthcare · $80M market cap
Verdict
We can't put a fair value on SERA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow SERA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 8, 2026: no open-market purchases and 5 sales worth $63K. Why purchases matter
Sales
Jackson Benjamin
General Counsel · 2026-09-10
Sold
$4K
Inglis Tiffany Eul Davis
Chief Medical Officer · 2026-09-10
Sold
$972
Lindgardt Zhenya
Chief Executive Officer · 2026-09-10
Sold
$14K
Anderson Dyaarl Lee Jr.
Chief Commercial Officer · 2026-09-10
Sold
$4K
Lindgardt Zhenya
Chief Executive Officer · 2026-09-08
Sold
$40K
About Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is…
Medical - Diagnostics & Research
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works